VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
VivoSim Labs, Inc. (VIVS)
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP-compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late-s
Show less
Read more
Impact Snapshot
Event Time:
VIVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIVS alerts
High impacting VivoSim Labs, Inc. news events
Weekly update
A roundup of the hottest topics
VIVS
News
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales [Yahoo! Finance]Yahoo! Finance
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesGlobeNewswire
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoGlobeNewswire
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China [Yahoo! Finance]Yahoo! Finance
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaGlobeNewswire
VIVS
Sec Filings
- 2/11/26 - Form 10-Q
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- VIVS's page on the SEC website